Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

BACKGROUND: Papillary renal cell carcinoma (pRCC) is associated with EGFR expression and activation of MET signaling pathway. A randomized multicenter parallel two-stage phase II trial of MET inhibitor tivantinib alone or in combination with EGFR inhibitor erlotinib was conducted in patients with pR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Kidney Cancer
Autors principals: Twardowski, Przemyslaw W., Tangen, Catherine M., Wu, Xiwei, Plets, Melissa R., Plimack, Elizabeth R., Agarwal, Neeraj, Vogelzang, Nicholas J., Wang, Jinhui, Tao, Shu, Thompson, Ian M., Lara, Primo
Format: Artigo
Idioma:Inglês
Publicat: IOS Press 2017
Matèries:
Research Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6179121/
https://ncbi.nlm.nih.gov/pubmed/30334014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/KCA-170018
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars